Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 115Squamous Cell Carcinoma of Head and Neck 61Triple Negative Breast Neoplasms 57Melanoma 54Neoplasm Metastasis 50Lung Neoplasms 50Breast Neoplasms 41Neoplasms 37Colorectal Neoplasms 36Carcinoma, Renal Cell 26Head and Neck Neoplasms 25Endometrial Neoplasms 25Stomach Neoplasms 22Uterine Cervical Neoplasms 21Ovarian Neoplasms 21Carcinoma, Transitional Cell 21Urinary Bladder Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 18Esophageal Neoplasms 16Recurrence 15Pancreatic Neoplasms 14Carcinoma, Hepatocellular 14Sarcoma 12Carcinoma, Squamous Cell 12Carcinoma 12Glioblastoma 11Esophageal Squamous Cell Carcinoma 11Prostatic Neoplasms 10Brain Neoplasms 10Carcinoma, Merkel Cell 9

Interventions

pembrolizumab 1X-Rays 1Taxes 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Congresses as Topic 1Cisplatin 1Carboplatin 1Brachytherapy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Locally Advanced Cervical Adenocarcinoma × pembrolizumab × Clear all
NCT07061977 2026-06-15

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
336 enrolled
Gynecologic

Locally Advanced Cervical Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡